Trump’s Return to the White House: Potential Implications for FDA and Biopharma M&A

Donald Trump's Victory:
Trump's win in the 2024 presidential election signals potential changes for federal health agencies and the industries they oversee.

Robert F. Kennedy Jr.'s Influence:
Trump's association with Robert F. Kennedy Jr., a critic of vaccines and the pharmaceutical industry, suggests unconventional policies may be on the horizon.

FDA Oversight:
A Trump administration could pay significant attention to the FDA, potentially leading to a shake-up in regulatory approaches.

M&A Impact:
Biotech leaders are cautiously optimistic about the potential impact of a Trump administration on federal oversight of mergers and acquisitions (M&A), which could be more favorable compared to the current FTC approach.

Drug Pricing:
Trump's administration could alter federal approaches to drug pricing, including revisiting policies like the "favoured nations" policy to control prices.

FTC Leadership:
The potential for changes in FTC leadership, particularly with Commissioner Rebecca Kelly Slaughter's term expiring in 2025, could influence M&A oversight.